Ambrisentan for the treatment of pulmonary arterial hypertension

Drug Design, Development and Therapy

Volumn , Issue 2, 2008, Pages 265-280

  Casserly, Brian ^a,c   Klinger, James R ^b,c  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Ambrisentan; Endothelin; Endothelin receptor antagonist; Pulmonary hypertension

Indexed keywords

AMBRISENTAN; AMINOTRANSFERASE; ANGIOTENSIN II; BERAPROST; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CARDIOTROPHIN 1; CATECHOLAMINE; CYTOKINE; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR ANTAGONIST; FREE RADICAL; GROWTH FACTOR; HEPARIN; ILOPROST; INSULIN; LU 208075; PLACEBO; PROSTACYCLIN; PROTEIN KINASE C; SILDENAFIL; SITAXSENTAN; THROMBIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; WARFARIN;

AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; BLOOD FLOW; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DNA SEQUENCE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENZYME BINDING; ENZYME SYNTHESIS; EXERCISE; FLUSHING; FOOD INDUSTRY; HEADACHE; HEART OUTPUT; HUMAN; HYPOXIA; LEUKOCYTE ACTIVATION; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG HEMODYNAMICS; MAXIMUM PLASMA CONCENTRATION; MUSCLE CONTRACTION; NAUSEA; NEBULIZATION; NOSE CONGESTION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; RHINOPHARYNGITIS; SHEAR STRESS; SIDE EFFECT; SINUSITIS; SMOOTH MUSCLE; STEADY STATE; SURVIVAL TIME; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VASOCONSTRICTION;

EID: 77953678901     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Alberts GF, Peifley KA, Johns A, et al. 1994. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem, 269:10112-10118 (Pubitemid 24196630)
2. Amberg W, Hergenroder S, Hillen H, et al. 1999. LU208075 and LU302146, two novel ETA-selective endothelin receptor antagonists: SAR of 3,3-diaryl propionic acid derivatives. International Conference on Endothelin, 6 October 10-13P.
3. Anand I, McMurray J, Cohn J, et al. 2004. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet, 364:347-354
4. Badesch DB, Abman SH, Ahearn GS, et al. 2004. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 126:35S-62S.
5. Barst RJ, Langleben D, Frost A, et al. 2004. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med, 169:441-447 (Pubitemid 38187114)
6. Barst RJ, Langleben D, Badesch D, et al. 2006. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol, 47:2049-2056
7. Battistini B, Berthiaume N, Kelland NF, et al. 2006. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood), 231:653-695
8. Bauer M, Wilkens H, Langer F, et al. 2002. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation, 105:1034-1036 (Pubitemid 34212609)
9. Bayes M, Rabasseda X, Prous JR. 2006. Gateways to clinical trials. Methods Find Exp Clin Pharmacol, 28:451-495
10. Benza RL, Barst RJ, Galie N, et al. 2008. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year,prospective, open-label observation of outcome and survival. Chest, 134:775-782
11. Billman GE. 2002, Ambrisentan (Myogen). Curr Opin Investig Drugs, 3:1483-1486
12. Black, SM, Mata-Greenwood E, Dettman RW, et al. 2003, Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation, 108:1646-1654 (Pubitemid 37187794)
13. Bolli MH, Marfurt J, Grisostomi C, et al. 2004, Novel benzo[1,4]diazepin- 2-one derivatives as endothelin receptor antagonists. J Med Chem, 47:2776-2795 (Pubitemid 38656731)
14. Boss C, Bolli M, Weller T. 2002. Endothelin receptor antagonists: structures, synthesis, selectivity and therapeutic applications. Curr Med Chem, 9:349-383 (Pubitemid 34441016)
15. Boulanger C, Luscher TF. 1990. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest, 85:587-590 (Pubitemid 20070070)
16. Budhiraja R, Tuder RM, Hassoun PM. 2004. Endothelial dysfunction in pulmonary hypertension. Circulation, 109:159-165
17. Cacoub P, Dorent R, Maistre, G, et al. 1993. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol, 71:448-450 (Pubitemid 23061514)
18. Cacoub P, Dorent R, Nataf P, et al. 1997. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res, 33:196-200. (Pubitemid 27019115)
19. Cernacek P, Franchi L, Dupuis J, et al. 1998. Radioreceptor assay of an endothelin A receptor antagonist in plasma and urine. Clin Chem, 44:1666-1673 (Pubitemid 28381208)
20. Chan SY, Loscalzo J. 2008. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol, 44:14-30.
21. Cheng JW. 2008. Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther, 30:825-833 (Pubitemid 351563831)
22. Clarke JG, Benjamin N, Larkin SW, et al. 1989. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol, 257:H2033-5. (Pubitemid 20023325)
23. Clozel M. 2003. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann Med, 35:605-613 (Pubitemid 38008038)
24. Clozel M, Breu V, Gray GA, et al. 1994. Phamacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther, 270:228-235 (Pubitemid 24229632)
25. Clozel M, Roux S. 2000. The pharmacology of endothelin and its antagonist bosentan. Ann Endocrinol (Paris), 61:75-79
26. D'Orleans-Juste P, Labonte J, Bkaily G, et al. 2002. Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther, 95:221-238 (Pubitemid 35247902)
27. Davie N, Haleen S J, Upton PD, et al. 2002. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med, 165:398-405.
28. De Nucci G, Thomas R, D'Orleans-Juste P, et al. 1988. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A, 85:9797-9800 (Pubitemid 19027212)
29. Dufton C, Gerber M, Yin O, et al. 2006. No clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil. Chest, 130:254S.
30. Dupuis J. 2000. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics. Can J Cardiol, 16:903-910 (Pubitemid 30639192)
31. Dupuis J, Goresky CA, Fournier A. 1996. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol, 81:1510-1515 (Pubitemid 26349600)
32. Emori T, Hirata Y, Ohta K, et al. 1991. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension, 18:165-170
33. Emoto N, Yanagisawa M. 1995. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem, 270:15262-15268
34. Feger GI, Schilling L, Ehrenreich H, et al. 1997. Endothelium-dependent relaxation counteracting the contractile action of endothelin-1 is partly due to ETB receptor activation. Res Exp Med (Berl), 196:327-337 (Pubitemid 27129345)
35. FDA/CDER Letairis (ambrisentan tablets) Clinical Pharmacology. Biopharmaceutics Review 3:98-99. Accessed May 28 2008. URL:http://www. fda.gov/cder/foi/nda/2007/022081s000-ClinPharmR-P3.pdf .
36. Frantz RP, Robbins IM, Durst LA, et al. 2008. Endothelin-1 and BNP plasma levels predict survival in patients with pulmonary arterial hypertension. Amer J Respir Crit Care Med, 177:A535.
37. Galie N, Badesch D, Oudiz R, et al. 2005. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 46:529-535 (Pubitemid 41040298)
38. Galie N, Beghetti M, Gatzoulis MA, et al. 2006. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation, 114:48-54. (Pubitemid 44305274)
39. Galie N, Keogh AM, Frost A, et al. 2005. Ambrisentan long-term safety and efficacy in pulmonary arterial hypertension-one year follow up. Proc Am Thorac Soc, 2:A299.
40. Galie N, Manes A, Branzi A. 2004. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res, 61:227-237 (Pubitemid 38091763)
41. Galie N, Olschewski H, Oudiz RJ, et al. 2008. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation, 117:3010-3019
42. Gerber MJ, Dufton C, Pentikis H, et al. 2006. Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin. Chest, 130:256S.
43. Gomberg-Maitland M, Olschewski H. 2008. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J, 31:891-901. (Pubitemid 352000589)
44. Granton J, Moric J. 2008. Pulmonary vasodilators - treating the right ventricle. Anesthesiol Clin, 26:337-53, vii. (Pubitemid 351626758)
45. Gray GA, Webb DJ. 1996. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther, 72:109-148 (Pubitemid 26423301)
46. Greene S, Nunley K, Weber S, et al. 2006. ETA vs ETB receptor selectivity of endothelin-1 receptor antagonists in human myocardial membranes. J Am Coll Cardiol, 47:307A.
47. Gregan B, Jurgensen J, Papsdorf G, et al. 2004. Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem, 279:27679-27687 (Pubitemid 38812609)
48. Guarda E, Katwa LC, Myers PR, et al. 1993. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res, 27:2130-2134 (Pubitemid 24034724)
49. Haynes WG, Webb DJ. 1992. Endothelin: a long-acting local constrictor hormone. Br J Hosp Med, 47:340-349
50. Hopfner R. 1999. Sixth International Conference on Endothelin (ET-6), Montreal, Canada. Meeting Report IDDB; October 10-13.
51. Hu RM, Levin ER, Pedram A, et al. 1992 Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells. Mediation through the C receptor. J Biol Chem, 267:17384-17389
52. Humbert M, Barst RJ, Robbins IM, et al. 2004a. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J, 24:353-359 (Pubitemid 39232254)
53. Humbert M, Sitbon O, Simonneau G. 2004b Treatment of pulmonary arterial hypertension. N Engl J Med, 351:1425-1436
54. Inoue A, Yanagisawa M, Kimura S, et al. 1989 The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A, 86:2863-2867 (Pubitemid 19112640)
55. Jacobs A, Preston IR, Gomberg-Maitland M. 2006 Endothelin receptor antagonism in pulmonary arterial hypertension - a role for selective ET(A) inhibition? Curr Med Res Opin, 22:2567-2574 (Pubitemid 46048372)
56. Janakidevi K, Fisher MA, Del Vecchio PJ, et al. 1992. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol, 263:C1295-301. (Pubitemid 23024437)
57. Jasmin JF, Lucas M, Cernacek P, et al. 2001. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation, 103:314-318 (Pubitemid 32095421)
58. Jeng AY, Mulder P, Kwan AL, et al. 2002. Nonpeptidic endothelin- converting enzyme inhibitors and their potential therapeutic applications. Can J Physiol Pharmacol, 80:440-449 (Pubitemid 34539420)
59. Jougasaki M, Larsen AM, Cataliotti A, et al. 2002. Cardiotrophin-1 stimulates endothelin-1 via gp130 in vascular endothelial cells. Peptides, 23:1441-1447 (Pubitemid 35223012)
60. Klipper E, Levy N, Gilboa T, et al. 2006. Identification of a novel alternatively spliced variant endothelin converting enzyme-1 lacking a transmembrane domain. Exp Biol Med (Maywood), 231:723-728 (Pubitemid 43845517)
61. Langleben D. 2007. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med, 28:117-25, viii. (Pubitemid 46330544)
62. Langleben D, Dupuis J, Langleben I, et al. 2006. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest, 129:689-695
63. Levin ER. 1995. Endothelins. N Engl J Med, 333:356-363
64. Liu C, Chen J. 2006. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev, 3, CD004434.
65. Love MP, McMurray JJ. 1996. Endothelin in chronic heart failure: current position and future prospects. Cardiovasc Res, 31:665-674 (Pubitemid 26175131)
66. Luscher TF, Barton M. 2000. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation, 102:2434-2440
67. Luscher TF, Enseleit F, Pacher R, et al. 2002. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation, 106:2666-2672
68. MaClean MR, McCulloch KM, Baird M. 1995. Effects of pulmonary hypertension on vasoconstrictor responses to endothelin-1 and sarafotoxin S6C and on inherent tone in rat pulmonary arteries. J Cardiovasc Pharmacol, 26:822-830
69. Masaki T, Kimura S, Yanagisawa M, et al. 1991. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation, 84:1457-1468
70. Masaki T, Miwa S, Sawamura T, Ninomiya H, et al. 1999. Subcellular mechanisms of endothelin action in vascular system. Eur J Pharmacol, 375:133-138 (Pubitemid 29317599)
71. Matsui K, Takano Y, Yu ZX, et al. 2002. Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy. Pathol Res Pract, 198:403-412 (Pubitemid 34823503)
72. McCulloch KM, Docherty C, MaClean MR. 1998. Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat. Br J Pharmacol, 123:1621-1630 (Pubitemid 28182045)
73. McCulloch KM, MaClean MR. 1995. EndothelinB receptor-mediated contraction of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat. J Cardiovasc Pharmacol, 26(Suppl 3):S169-76.
74. McGoon M, Frost A, Oudiz R, et al. 2006. Ambrisentan rescue therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function abnormalities. Chest, 130:254S.
75. McGoon MD, Frost AE, Oudiz RJ, 2008. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. [Epub ahead of print].
76. Meidan R, Klipper E, Gilboa T, et al. 2005. Endothelin-converting enzyme-1, abundance of isoforms a-d and identification of a novel alternatively spliced variant lacking a transmembrane domain. J Biol Chem, 280:40867-40874 (Pubitemid 41780579)
77. Miwa S, Iwamuro Y, Zhang XF, et al. 1999. Ca2+ entry channels in rat thoracic aortic smooth muscle cells activated by endothelin-1. Jpn J Pharmacol, 80:281-288 (Pubitemid 29431371)
78. Morimoto H, Shimadzu H, Kushiyama E, et al. 2001. Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives. J Med Chem, 44:3355-3368 (Pubitemid 32947902)
79. Motte S, McEntee K, Naeije R. 2006. Endothelin receptor antagonists. Pharmacol Ther, 110:386-414.
80. Mullol J, Baraniuk JN, Logun C. 1996. Endothelin-1 induces GM-CSF, IL-6 and IL-8 but not G-CSF release from a human bronchial epithelial cell line (BEAS-2B). Neuropeptides, 30:551-556 (Pubitemid 27013981)
81. Nagaya N, Nishikimi T, Uematsu M, et al. 2000. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation, 102:865-870
82. Niwa Y, Nagata N, Oka M, et al. 2000. Production of nitric oxide from endothelial cells by 31-amino-acid-length endothelin-1, a novel vasoconstrictive product by human chymase. Life Sci, 67:1103-1109 (Pubitemid 30485814)
83. Nootens M, Kaufmann E, Rector T, et al. 1995. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol, 26:1581-1585
84. Ohlstein EH, Arleth A, Bryan H, et al. 1992. The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol, 225:347-350
85. Opgenorth TJ, Wu-Wong JR, Shiosaki K. 1992. Endothelin-converting enzymes. FASEB J, 6:2653-2659
86. Opitz, CF, Ewert R, Kirch W, et al. 2008. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J.
87. Pollock DM, Keith TL, Highsmith RF. 1995. Endothelin receptors and calcium signaling. FASEB J, 9:1196-1204
88. Prie S, Leung TK, Cernacek P, et al. 1997. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)- 3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther, 282:1312-1318 (Pubitemid 27408309)
89. Prins BA, Hu RM, Nazario B, et al. 1994. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem, 269:11938-11944 (Pubitemid 24196684)
90. Provencher S, Sitbon O, Humbert M, et al. 2006. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J, 27:589-595
91. Rich S, McLaughlin VV, 2003. Endothelin receptor blockers in cardiovascular disease. Circulation, 108:2184-2190 (Pubitemid 37363032)
92. Riechers H, Albrecht HP, Amber W, et al. 1996. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem, 39:2123-2128 (Pubitemid 26173247)
93. Rubanyi GM, Polokoff MA. 1994. Endothelins: molecular biology, bio-chemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev, 46:325-415.
94. Rubin LJ, Badesch DB, Barst RJ. 2002. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 346:896-903. (Pubitemid 34984638)
95. Rubin LJ, Dufton C Gerber MJ. 2005. Ambrisentan for pulmonary arterial hypertension. Future Cardiol, 1:1-8.
96. Russell FD, Davenport AP. 1999. Secretory pathways in endothelin synthesis. Br J Pharmacol, 126:391-398
97. Schiffrin EL. 2005. Vascular endothelin in hypertension. Vascul Pharmacol, 43:19-29.
98. Schmidt M, Kroger B, Jacob E, et al. 1994. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett, 356:238-243 (Pubitemid 24376980)
99. Schroll S, Arzt M, Sebah D, et al. 2008. Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension. Scand J Clin Lab Invest, 68:270-276 (Pubitemid 351962405)
100. Seo B, Oemar BS, Siebenmann R, et al. 1994. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation, 89:1203-1208 (Pubitemid 24076547)
101. Shi-Wen X, Chen Y, Denton CP, et al. 2004. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell, 15:2707-2719 (Pubitemid 38691860)
102. Shimada K, Takahashi M, Tanzawa K. 1994. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem, 269:18275-18278 (Pubitemid 24224046)
103. Simonson MS, Dunn MJ. 1990. Cellular signaling by peptides of the endothelin gene family. FASEB J, 4:2989-3000.
104. Sirvio ML, Metsarinne K, Saijonmaa O, et al. 1990. Tissue distribution and half-life of 125I-endothelin in the rat: importance of pulmonary clearance. Biochem Biophys Res Commun, 167:1191-1195 (Pubitemid 20113307)
105. Sitbon O, Gressin V, Speich R, et al. 2004. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med, 170:1212-1217 (Pubitemid 39577380)
106. Stewart DJ, Levy RD, Cernacek P, et al. 1991. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med, 114:464-469
107. Takahashi M, Matsushita Y, Iijima Y, et al. 1993. Purification and characterization of endothelin-converting enzyme from rat lung. J Biol Chem, 268:21394-21398 (Pubitemid 23292333)
108. Torres F. 2007. Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension. Int J Clin Pract, 61:1756-1765 (Pubitemid 47404403)
109. Tuder RM, Cool CD, Yeager M, et al. 2001. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med, 22:405-418
110. Tuder RM, Marecki JC, Richter A, et al. 2007. Pathology of pulmonary hypertension. Clin Chest Med, 28:23-42, vii.
111. Valdenaire O, Lepailleur-Enouf D, Egidy G, et al. 1999. A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization. Eur J Biochem, 264:341-349 (Pubitemid 29424437)
112. Vatter H, Seifert V. 2006. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev, 24:63-76. (Pubitemid 46696785)
113. Vatter H, Zimmermann M, Weyrauch E, et al. 2003. Cerebrovascular characterization of the novel nonpeptide endothelin-A receptor antagonist LU 208075. Clin Neuropharmacol, 26:73-83. (Pubitemid 36397363)
114. Verhaar MC, Strachan FE, Newby DE, et al. 1998. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation, 97:752-756
115. Vierhapper H, Wagner O, Nowotny P, et al. 1990. Effect of endothelin-1 in man. Circulation, 81:1415-1418
116. Wagner OF, Christ G, Wojta J, et al. 1992. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem, 267:16066-16068
117. Xu D, Emoto N, Giaid A, et al. 1994. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell, 78:473-485 (Pubitemid 24250811)
118. Yanagisawa H, Hammer RE, Richardson JA, et al. 2000. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest, 105:1373-1382 (Pubitemid 30322403)
119. Yanagisawa M, Kurihara H, Kimura S, et al. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332:411-415 (Pubitemid 18090241)
120. Yokokawa K, Tahara H, Kohno M, et al. 1993. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest, 92:2080-2085 (Pubitemid 23304581)